Posts tagged NASDAQ:GLMD
Maxim cuts Galmed Pharma price target to $9

Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The stock was changing hands at $4.26 in Monday afternoon trading.

Analyst Jason Kolbert writes that the next major inflection point for Galmed is proof-of-concept data for Aramchol in nonalcoholic steatohepatitis (NASH) in 2018.

Read More
HCW assumes coverage of Galmed at buy

H.C. Wainwright analyst, Ed Arce, has assumed coverage of Galmed Pharmaceuticals (NASDAQ:GLMD) with a “buy” rating and $22 price target. The stock closed at $4.44 on Friday.

Galmed is focused on the development of a sole drug candidate, aramchol, as a potentially disease-modifying treatment for nonalcoholic steatohepatitis (NASH).

Read More